MedTrace Logo

Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis

NCT01056471 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-08-07

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with mesenchymal stem cells from adipose tissue, administered intravenously in patients with secondary progressive multiple sclerosis who do not respond to treatment.

Conditions

  • Autoimmune Diseases
  • Immune System Diseases
  • Demyelinating Diseases
  • Nervous System Diseases
  • Demyelinating Autoimmune Diseases, CNS
  • Autoimmune Diseases of the Nervous System

Interventions

OTHER

Autologous mesenchymal stem cells from adipose tissue.

Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg.

OTHER

Autologous mesenchymal stem cells from adipose tissue.

Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.

Sponsors & Collaborators

  • Carlos III Health Institute

    collaborator OTHER_GOV

  • Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud

    lead OTHER

Principal Investigators

  • Oscar Fernandez Fernandez, MD, PhD · Hospital Regional Universitario Carlos Haya, Málaga, Spain.

  • Guillermo Izquierdo Ayuso, MD, PhD · Hospital Universitario Virgen Macarena, Sevilla, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-06-30
Completion
2015-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056471 on ClinicalTrials.gov